Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TD Cowen Reiterates Hold Rating on Fate Therapeutics (FATE)
November 18, 2024 11:22 AM ESTTD Cowen analyst Tara Bancroft reiterated a Hold rating on Fate Therapeutics (NASDAQ: FATE).
The analyst commented, "The first SLE patient treated with FT819 (iCAR-T) is now past 6 months with ongoing clinical remission, low disease activity, and resolution of key quality of life... More
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study
November 18, 2024 8:05 AM ESTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C. The patient, a 27-year-old African American-Asian woman diagnosed with lupus nephritis (LN) over ten years ago, received fludarabine-free conditioning followed by a single dose of... More
